The role of pharmacists in the management of neuropsychiatric disorders is an evolving area within healthcare, driven by the need for effective treatment options for mental illnesses affecting over 50 million Americans. This review examines the critical interventions provided by pharmacists to optimize treatment in neuropsychiatric disorders, emphasizing the multi-faceted nature of their contributions within healthcare teams. Pharmacists’ interventions include medication management, adherence, patient counseling, and other methods that support the prevention of adverse events, and they are key players in enhancing mental health care through collaborative practice models. Objectives: The primary objective of this review is to evaluate the impact of pharmacist-led interventions on patient outcomes in the management of neuropsychiatric disorders, exploring their roles in various settings and collaborative environments. Background: Neuropsychiatric disorders, which span both psychiatric and neurologic conditions, require comprehensive and integrated care approaches. Pharmacists are increasingly involved in medication management, patient education, and adherence strategies essential for managing these disorders effectively. Methods: A literature review was conducted to analyze studies examining pharmacist-led interventions in neuropsychiatric care, including adherence programs, medication reconciliation, adverse event monitoring, and pharmacogenomic applications. Articles were selected based on their focus on pharmacist interventions in community, hospital, and interdisciplinary settings. Results: Evidence suggests that pharmacist-led interventions improve adherence, optimize medication management, and contribute to reducing readmissions in patients with neuropsychiatric disorders. Key findings highlight the success of interventions such as patient counseling, pharmacogenomic-guided therapy, and collaborative care models, demonstrating improved outcomes across various settings. Conclusions: Pharmacists play a critical role in managing neuropsychiatric disorders through comprehensive medication management, patient education, and collaboration with other healthcare providers. Their involvement is essential for safe, effective, and personalized mental health care, underscoring the need to further integrate pharmacists in mental health services.
References
[1]
NIMH (2024) Mental Illness—National Institute of Mental Health. https://www.nimh.nih.gov/health/statistics/mental-illness
[2]
World Health Organization (2024) Neuropsychiatric Conditions. https://platform.who.int/mortality
[3]
Taslim, S., Shadmani, S., Saleem, A.R., Kumar, A., Brahma, F., Blank, N., et al. (2024) Neuropsychiatric Disorders: Bridging the Gap between Neurology and Psychiatry. Cureus, 16, e51655. https://doi.org/10.7759/cureus.51655
[4]
Goldstone, L.W., DiPaula, B.A., Caballero, J., Park, S.H., Price, C. and Slater, M.Z. (2015) Improving Medication-Related Outcomes for Patients with Psychiatric and Neurologic Disorders: Value of Psychiatric Pharmacists as Part of the Health Care Team. Mental Health Clinician, 5, 1-28. https://doi.org/10.9740/mhc.2015.01.001
[5]
Ng, R., El-Den, S., Stewart, V., Collins, J.C., Roennfeldt, H., McMillan, S.S., et al. (2021) Pharmacist-led Interventions for People Living with Severe and Persistent Mental Illness: A Systematic Review. Australian & New Zealand Journal of Psychiatry, 56, 1080-1103. https://doi.org/10.1177/00048674211048410
[6]
Spaulding, A.M. (2012) A Pharmacotherapeutic Approach to the Management of Chronic Posttraumatic Stress Disorder. Journal of Pharmacy Practice, 25, 541-551. https://doi.org/10.1177/0897190012442714
Samaksha, P.B., Kishor, M. and Ramesh, M. (2022) A Novel Study on Clinical Pharmacist and Psychiatrist Collaborative Pharmacotherapy Management Services among Elderly Population with Psychiatric Illness. Indian Journal of Psychiatry, 64, 20-24. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_379_21
[9]
Readdean, K.C., Heuer, A.J. and Scott Parrott, J. (2018) Effect of Pharmacist Intervention on Improving Antidepressant Medication Adherence and Depression Symptomology: A Systematic Review and Meta-Analysis. Research in Social and Administrative Pharmacy, 14, 321-331. https://doi.org/10.1016/j.sapharm.2017.05.008
[10]
Rubio-Valera, M., Serrano-Blanco, A., Magdalena-Belío, J., Fernández, A., García-Campayo, J., March Pujol, M., et al. (2011) Effectiveness of Pharmacist Care in the Improvement of Adherence to Antidepressants: A Systematic Review and Meta-Analysis. Annals of Pharmacotherapy, 45, 39-48. https://doi.org/10.1345/aph.1p429
[11]
Cahaya, N., Kristina, S.A., Widayanti, A.W. and Green, J. (2022) Interventions to Improve Medication Adherence in People with Schizophrenia: A Systematic Review. Patient Preference and Adherence, 16, 2431-2449. https://doi.org/10.2147/ppa.s378951
[12]
Khorassani, F., Tellier, S. and Tsapepas, D. (2018) Pharmacist’s Role in Improving Medication Adherence in Transplant Recipients with Comorbid Psychiatric Disorders. Journal of Pharmacy Practice, 32, 568-578. https://doi.org/10.1177/0897190018764074
[13]
Bingham, J., Silva-Almodóvar, A., Lee, H., Benson, C., Michael, R., Azurin, C., et al. (2020) The Role of the Pharmacist in Mental Health: An Investigation of the Impact of Pharmacist-Led Interventions on Psychotropic Medication Adherence in Patients with Diabetes. Journal of the American Pharmacists Association, 60, e58-e63. https://doi.org/10.1016/j.japh.2020.01.009
[14]
Alkoudsi, K.T. and Basheti, I.A. (2020) Prevalence of Anxiety and Depression among Women with Polycystic Ovary Syndrome Living in War versus Non-War Zone Countries: A Randomized Controlled Trial Assessing a Pharmacist Intervention. Research in Social and Administrative Pharmacy, 16, 689-698. https://doi.org/10.1016/j.sapharm.2019.08.027
Fatima, S., Arshad, A., Zafar, A., Farrukh, S., Rahim, A., Nazar, S., et al. (2024) Journey of Medication Reconciliation Compliance in a Lower Middle-Income Country: A Retrospective Chart Review. BMJ Open Quality, 13, e002527. https://doi.org/10.1136/bmjoq-2023-002527
[17]
American Pharmacists Association and American Society of Health-System Phar-macist (2012) Improving Care Transitions: Optimizing Medication Reconciliation. Journal of the American Pharmacists Association, 52, e43-e52. https://doi.org/10.1331/japha.2012.12527
[18]
Javelot, H., Gitahy Falcao Faria, C., Vandenberghe, F., Dizet, S., Langrée, B., Le Maout, M., et al. (2021) Clinical Pharmacy in Psychiatry: Towards Promoting Clinical Expertise in Psychopharmacology. Pharmacy, 9, Article 146. https://doi.org/10.3390/pharmacy9030146
[19]
Herbert, C., Winkler, H. and Moore, T.A. (2017) Outcomes of Mental Health Pharmacist-Managed Electronic Consults at a Veterans Affairs Health Care System. Mental Health Clinician, 7, 131-136. https://doi.org/10.9740/mhc.2017.05.131
[20]
Gotlib, D., Bostwick, J.R., Calip, S., et al. (2017) Collaborative Care in Ambulatory Psychiatry: Content Analysis of Consultations to a Psychiatric Pharmacist. Psychopharmacol Bull, 47, 41-46.
[21]
Hahn, M., Stuhec, M. and da Costa, F.A. (2023) Overview of This Issue: Clinical Pharmacy Impacting Mental Health Delivery and Outcomes. International Journal of Clinical Pharmacy, 45, 1025-1026. https://doi.org/10.1007/s11096-023-01654-1
[22]
Farag, M., Chalmers, L., Hoti, K. and Hughes, J. (2022) The Role of the Clinical Pharmacist in Mental Health Hospital-In-The-Home: A Scoping Review. Research in Social and Administrative Pharmacy, 18, 3724-3735. https://doi.org/10.1016/j.sapharm.2022.04.004
Kelling, S.E., Rondon-Begazo, A., DiPietro Mager, N.A., Murphy, B.L. and Bright, D.R. (2016) Provision of Clinical Preventive Services by Community Pharmacists. Preventing Chronic Disease, 13, Article 160232. https://doi.org/10.5888/pcd13.160232
[25]
Karp, J.F., Kincman, J., Lightfoot, M., Foust, J.E., Maher, R. and Gebara, M.A. (2022) A Systematic Review of Community Pharmacy Initiatives to Improve Treatment of Depression and Pain: Focus on Types of Programs and Patient-Reported Outcomes. Research in Social and Administrative Pharmacy, 18, 2569-2578. https://doi.org/10.1016/j.sapharm.2021.05.015
[26]
Chung, B., Dopheide, J.A. and Gregerson, P. (2011) Psychiatric Pharmacist and Primary Care Collaboration at a Skid-Row Safety-Net Clinic. Journal of the National Medical Association, 103, 567-575. https://doi.org/10.1016/s0027-9684(15)30382-5
[27]
Reid, S., Nichols, R., Veach, S., Alhersh, E. and Witry, M. (2024) Evaluation of an Enhanced Depression and Anxiety Screening with Targeted Pharmacist Intervention. Journal of the American Pharmacists Association, 64, Article 102067. https://doi.org/10.1016/j.japh.2024.102067
[28]
Wilson, C. and Twigg, G. (2018) Pharmacist-Led Depression Screening and Intervention in an Underserved, Rural, and Multi-Ethnic Diabetic Population. Journal of the American Pharmacists Association, 58, 205-209. https://doi.org/10.1016/j.japh.2017.11.001
[29]
Lam, R.W., Kennedy, S.H., Adams, C., Bahji, A., Beaulieu, S., Bhat, V., et al. (2024) Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l’humeur et de l'anxiété (CANMAT) 2023: Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. The Canadian Journal of Psychiatry, 69, 641-687. https://doi.org/10.1177/07067437241245384
[30]
Karge, R., Curtain, C. and Salahudeen, M. (2023) Community Pharmacists’ Role in Reducing the Incidence of Cardiometabolic Adverse Drug Events in Schizophrenia: Insights from Mental Health Professionals. Medicina, 59, Article 2052. https://doi.org/10.3390/medicina59122052
[31]
Cummings, J.L. and Jeste, D.V. (2007) Pharmacotherapy of Neuropsychiatric Syndromes in Neurologic Disorders: Definitional and Regulatory Aspects. Psychopharmacol Bull, 40, 89-98.
[32]
Pain Management and MOUD Resource Center—ASHP. https://www.ashp.org/Pharmacy-Practice/Resource-Centers/pain-management-and-moud-resource-center
[33]
Thapa, P., Lee, S.W.H., KC, B., Dujaili, J.A., Mohamed Ibrahim, M.I. and Gyawali, S. (2021) Pharmacist-Led Intervention on Chronic Pain Management: A Systematic Review and Meta-Analysis. British Journal of Clinical Pharmacology, 87, 3028-3042. https://doi.org/10.1111/bcp.14745
[34]
Iqbal, A., David Knaggs, R., Anderson, C. and Toh, L.S. (2022) Role of Pharmacists in Optimising Opioid Therapy for Chronic Non-Malignant Pain; A Systematic Review. Research in Social and Administrative Pharmacy, 18, 2352-2366. https://doi.org/10.1016/j.sapharm.2020.11.014
[35]
Pottie, K., Thompson, W., Davies, S., et al. (2018) Deprescribing Benzodiazepine Receptor Agonists: Evidence-Based Clinical Practice Guideline. Canadian Family Physician, 64, 339-351.
[36]
Bjerre, L.M., Farrell, B., Hogel, M., et al. (2018) Deprescribing Antipsychotics for Behavioural and Psychological Symptoms of Dementia and Insomnia: Evidence-Based Clinical Practice Guideline. Canadian Family Physician, 64, 17-27.
[37]
Haidar, C., Petry, N., Oxencis, C., Douglas, J.S. and Hoffman, J.M. (2021) ASHP Statement on the Pharmacist’s Role in Clinical Pharmacogenomics. American Journal of Health-System Pharmacy, 79, 704-707. https://doi.org/10.1093/ajhp/zxab339
[38]
Stäuble, C.K., Lampert, M.L., Allemann, S., Hatzinger, M., Hersberger, K.E., Meyer zu Schwabedissen, H.E., et al. (2021) Pharmacist-Guided Pre-Emptive Pharmacogenetic Testing in Antidepressant Therapy (PrePGx): Study Protocol for an Open-Label, Randomized Controlled Trial. Trials, 22, Article No. 919. https://doi.org/10.1186/s13063-021-05724-5
[39]
Alchakee, A., Ahmed, M., Eldohaji, L., Alhaj, H. and Saber-Ayad, M. (2022) Pharmacogenomics in Psychiatry Practice: The Value and the Challenges. International Journal of Molecular Sciences, 23, Article 13485. https://doi.org/10.3390/ijms232113485
[40]
Mojtabai, R. (2009) Unmet Need for Treatment of Major Depression in the United States. Psychiatric Services, 60, 297-305. https://doi.org/10.1176/ps.2009.60.3.297
[41]
Bättig, V.A.D., Roll, S.C. and Hahn, M. (2020) Pharmacogenetic Testing in Depressed Patients and Interdisciplinary Exchange between a Pharmacist and Psychiatrists Results in Reduced Hospitalization Times. Pharmacopsychiatry, 53, 185-192. https://doi.org/10.1055/a-1096-1171
[42]
Bousman, C.A., Bengesser, S.A., Aitchison, K.J., Amare, A.T., Aschauer, H., Baune, B.T., et al. (2020) Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry, 54, 5-17. https://doi.org/10.1055/a-1288-1061
[43]
Mathys, M., Neyland-Turner, E., Hamouie, K. and Kim, E. (2015) Effect of Pharmacy Students as Primary Pharmacy Members on Inpatient Interdisciplinary Mental Health Teams. American Journal of Health-System Pharmacy, 72, 663-667. https://doi.org/10.2146/ajhp140411
[44]
Frick, A., Osae, L., Ngo, S., Anksorus, H., Williams, C.R., Rodgers, P.T., et al. (2021) Establishing the Role of the Pharmacist in Mental Health: Implementing Mental Health First Aid into the Doctor of Pharmacy Core Curriculum. Currents in Pharmacy Teaching and Learning, 13, 608-615. https://doi.org/10.1016/j.cptl.2021.01.027
[45]
Bell, J.S., Rosen, A., Aslani, P., Whitehead, P. and Chen, T.F. (2007) Developing the Role of Pharmacists as Members of Community Mental Health Teams: Perspectives of Pharmacists and Mental Health Professionals. Research in Social and Administrative Pharmacy, 3, 392-409. https://doi.org/10.1016/j.sapharm.2006.10.005
[46]
Stuhec, M. and Tement, V. (2021) Positive Evidence for Clinical Pharmacist Interventions during Interdisciplinary Rounding at a Psychiatric Hospital. Scientific Reports, 11, Article 13641. https://doi.org/10.1038/s41598-021-92909-2
